Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Zendy

Bernard Zinman | Zendy; Christoph Wanner | Zendy; John M. Lachin | Zendy; David Fitchett | Zendy; Erich Bluhmki | Zendy; Stefan Hantel | Zendy; Michaela Mattheus | Zendy; Theresa Devins | Zendy; Odd Erik Johansen | Zendy; Hans J. Woerle | Zendy; Uli C. Broedl | Zendy; Silvio E. Inzucchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Author(s) -

Bernard Zinman,

Christoph Wanner,

John M. Lachin,

David Fitchett,

Erich Bluhmki,

Stefan Hantel,

Michaela Mattheus,

Theresa Devins,

Odd Erik Johansen,

Hans J. Woerle,

Uli C. Broedl,

Silvio E. Inzucchi

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1504720

Subject(s) - empagliflozin , medicine , hazard ratio , myocardial infarction , placebo , confidence interval , relative risk , diabetes mellitus , stroke (engine) , angina , type 2 diabetes , cardiology , endocrinology , mechanical engineering , alternative medicine , pathology , engineering

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research